The  ||| S:0 E:4 ||| DT
Human  ||| S:4 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
Economic  ||| S:14 E:23 ||| NNP
Burden  ||| S:23 E:30 ||| NNP
of  ||| S:30 E:33 ||| IN
Difficult-to-Treat  ||| S:33 E:52 ||| NNP
Gouty  ||| S:52 E:58 ||| NNP
Arthritis  ||| S:58 E:68 ||| NNP
Gouty  ||| S:68 E:74 ||| NNP
arthritis ||| S:74 E:83 ||| NN
,  ||| S:83 E:85 ||| ,
one  ||| S:85 E:89 ||| CD
of  ||| S:89 E:92 ||| IN
the  ||| S:92 E:96 ||| DT
most  ||| S:96 E:101 ||| RBS
painful  ||| S:101 E:109 ||| JJ
and  ||| S:109 E:113 ||| CC
common  ||| S:113 E:120 ||| JJ
forms  ||| S:120 E:126 ||| NNS
of  ||| S:126 E:129 ||| IN
adult  ||| S:129 E:135 ||| NN
arthritis ||| S:135 E:144 ||| NN
,  ||| S:144 E:146 ||| ,
is  ||| S:146 E:149 ||| VBZ
caused  ||| S:149 E:156 ||| VBN
by  ||| S:156 E:159 ||| IN
monosodium  ||| S:159 E:170 ||| JJ
urate  ||| S:170 E:176 ||| JJ
crystal  ||| S:176 E:184 ||| NN
deposits  ||| S:184 E:193 ||| NNS
in  ||| S:193 E:196 ||| IN
joints ||| S:196 E:202 ||| NNS
,  ||| S:202 E:204 ||| ,
most  ||| S:204 E:209 ||| RBS
often  ||| S:209 E:215 ||| RB
in  ||| S:215 E:218 ||| IN
the  ||| S:218 E:222 ||| DT
lower  ||| S:222 E:228 ||| JJR
extremities ||| S:228 E:239 ||| NN
.  ||| S:239 E:241 ||| .
Crystals  ||| S:241 E:250 ||| NNS
trigger  ||| S:250 E:258 ||| VBP
an  ||| S:258 E:261 ||| DT
inflammatory  ||| S:261 E:274 ||| JJ
response  ||| S:274 E:283 ||| NN
leading  ||| S:283 E:291 ||| VBG
to  ||| S:291 E:294 ||| TO
acute  ||| S:294 E:300 ||| VB
flares  ||| S:300 E:307 ||| VBN
characterized  ||| S:307 E:321 ||| VBN
by  ||| S:321 E:324 ||| IN
a  ||| S:324 E:326 ||| DT
rapid  ||| S:326 E:332 ||| JJ
onset  ||| S:332 E:338 ||| NN
of  ||| S:338 E:341 ||| IN
pain ||| S:341 E:345 ||| NN
,  ||| S:345 E:347 ||| ,
warmth ||| S:347 E:353 ||| NN
,  ||| S:353 E:355 ||| ,
swelling ||| S:355 E:363 ||| VBG
,  ||| S:363 E:365 ||| ,
and  ||| S:365 E:369 ||| CC
redness  ||| S:369 E:377 ||| NN
in  ||| S:377 E:380 ||| IN
involved  ||| S:380 E:389 ||| JJ
joints ||| S:389 E:395 ||| NNS
.  ||| S:395 E:397 ||| .
Over  ||| S:397 E:402 ||| IN
time ||| S:402 E:406 ||| NN
,  ||| S:406 E:408 ||| ,
continued  ||| S:408 E:418 ||| VBD
monosodium  ||| S:418 E:429 ||| JJ
urate  ||| S:429 E:435 ||| JJ
crystal  ||| S:435 E:443 ||| NN
deposits  ||| S:443 E:452 ||| NNS
and  ||| S:452 E:456 ||| CC
inflammation  ||| S:456 E:469 ||| NNS
can  ||| S:469 E:473 ||| MD
lead  ||| S:473 E:478 ||| VB
to  ||| S:478 E:481 ||| TO
chronic  ||| S:481 E:489 ||| VB
tophaceous  ||| S:489 E:500 ||| JJ
gout  ||| S:500 E:505 ||| NN
that  ||| S:505 E:510 ||| IN
result  ||| S:510 E:517 ||| NN
in  ||| S:517 E:520 ||| IN
bone  ||| S:520 E:525 ||| NN
erosion ||| S:525 E:532 ||| NN
,  ||| S:532 E:534 ||| ,
progressing  ||| S:534 E:546 ||| VBG
to  ||| S:546 E:549 ||| TO
joint  ||| S:549 E:555 ||| JJ
destruction  ||| S:555 E:567 ||| NN
and  ||| S:567 E:571 ||| CC
significant  ||| S:571 E:583 ||| JJ
disability ||| S:583 E:593 ||| NN
.  ||| S:593 E:595 ||| .
The  ||| S:595 E:599 ||| DT
goal  ||| S:599 E:604 ||| NN
of  ||| S:604 E:607 ||| IN
therapy  ||| S:607 E:615 ||| NN
in  ||| S:615 E:618 ||| IN
an  ||| S:618 E:621 ||| DT
acute  ||| S:621 E:627 ||| JJ
gout  ||| S:627 E:632 ||| JJ
flare  ||| S:632 E:638 ||| NN
is  ||| S:638 E:641 ||| VBZ
prompt  ||| S:641 E:648 ||| JJ
and  ||| S:648 E:652 ||| CC
safe  ||| S:652 E:657 ||| JJ
termination  ||| S:657 E:669 ||| NN
of  ||| S:669 E:672 ||| IN
pain  ||| S:672 E:677 ||| NN
and  ||| S:677 E:681 ||| CC
inflammation ||| S:681 E:693 ||| NN
.  ||| S:693 E:695 ||| .
Acute  ||| S:695 E:701 ||| JJ
gouty  ||| S:701 E:707 ||| JJ
arthritis  ||| S:707 E:717 ||| NN
is  ||| S:717 E:720 ||| VBZ
usually  ||| S:720 E:728 ||| RB
treated  ||| S:728 E:736 ||| VBN
with  ||| S:736 E:741 ||| IN
nonsteroidal  ||| S:741 E:754 ||| JJ
anti-inflammatory  ||| S:754 E:772 ||| JJ
drugs ||| S:772 E:777 ||| NNS
,  ||| S:777 E:779 ||| ,
colchicine ||| S:779 E:789 ||| NN
,  ||| S:789 E:791 ||| ,
or  ||| S:791 E:794 ||| CC
corticosteroids ||| S:794 E:809 ||| NN
.  ||| S:809 E:811 ||| .
However ||| S:811 E:818 ||| RB
,  ||| S:818 E:820 ||| ,
for  ||| S:820 E:824 ||| IN
a  ||| S:824 E:826 ||| DT
growing  ||| S:826 E:834 ||| VBG
number  ||| S:834 E:841 ||| NN
of  ||| S:841 E:844 ||| IN
patients ||| S:844 E:852 ||| NNS
,  ||| S:852 E:854 ||| ,
current  ||| S:854 E:862 ||| JJ
standard  ||| S:862 E:871 ||| JJ
treatments  ||| S:871 E:882 ||| NNS
are  ||| S:882 E:886 ||| VBP
ineffective  ||| S:886 E:898 ||| JJ
or  ||| S:898 E:901 ||| CC
are  ||| S:901 E:905 ||| VBP
contraindicated ||| S:905 E:920 ||| VBN
,  ||| S:920 E:922 ||| ,
largely  ||| S:922 E:930 ||| RB
due  ||| S:930 E:934 ||| JJ
to  ||| S:934 E:937 ||| TO
the  ||| S:937 E:941 ||| DT
presence  ||| S:941 E:950 ||| NN
of  ||| S:950 E:953 ||| IN
comorbidities ||| S:953 E:966 ||| NN
.  ||| S:966 E:968 ||| .
Gouty  ||| S:968 E:974 ||| JJ
arthritis  ||| S:974 E:984 ||| NN
can  ||| S:984 E:988 ||| MD
have  ||| S:988 E:993 ||| VB
a  ||| S:993 E:995 ||| DT
major  ||| S:995 E:1001 ||| JJ
negative  ||| S:1001 E:1010 ||| JJ
impact  ||| S:1010 E:1017 ||| NN
of  ||| S:1017 E:1020 ||| IN
health-related  ||| S:1020 E:1035 ||| JJ
quality  ||| S:1035 E:1043 ||| NN
of  ||| S:1043 E:1046 ||| IN
life ||| S:1046 E:1050 ||| NN
,  ||| S:1050 E:1052 ||| ,
especially  ||| S:1052 E:1063 ||| RB
in  ||| S:1063 E:1066 ||| IN
patients  ||| S:1066 E:1075 ||| NNS
with  ||| S:1075 E:1080 ||| IN
difficult-to-treat  ||| S:1080 E:1099 ||| JJ
disease ||| S:1099 E:1106 ||| NN
,  ||| S:1106 E:1108 ||| ,
as  ||| S:1108 E:1111 ||| RB
revealed  ||| S:1111 E:1120 ||| VBN
by  ||| S:1120 E:1123 ||| IN
recent  ||| S:1123 E:1130 ||| JJ
studies  ||| S:1130 E:1138 ||| NNS
comparing  ||| S:1138 E:1148 ||| VBG
health-related  ||| S:1148 E:1163 ||| JJ
quality  ||| S:1163 E:1171 ||| NN
of  ||| S:1171 E:1174 ||| IN
life  ||| S:1174 E:1179 ||| NN
with  ||| S:1179 E:1184 ||| IN
that  ||| S:1184 E:1189 ||| DT
of  ||| S:1189 E:1192 ||| IN
the  ||| S:1192 E:1196 ||| DT
general  ||| S:1196 E:1204 ||| JJ
population ||| S:1204 E:1214 ||| NN
.  ||| S:1214 E:1216 ||| .
Additionally ||| S:1216 E:1228 ||| RB
,  ||| S:1228 E:1230 ||| ,
gouty  ||| S:1230 E:1236 ||| JJ
arthritis  ||| S:1236 E:1246 ||| NN
also  ||| S:1246 E:1251 ||| RB
constitutes  ||| S:1251 E:1263 ||| VBZ
an  ||| S:1263 E:1266 ||| DT
important  ||| S:1266 E:1276 ||| JJ
economic  ||| S:1276 E:1285 ||| JJ
burden  ||| S:1285 E:1292 ||| NN
through  ||| S:1292 E:1300 ||| IN
absence  ||| S:1300 E:1308 ||| NN
from  ||| S:1308 E:1313 ||| IN
work  ||| S:1313 E:1318 ||| NN
and  ||| S:1318 E:1322 ||| CC
medical  ||| S:1322 E:1330 ||| JJ
costs ||| S:1330 E:1335 ||| NNS
.  ||| S:1335 E:1337 ||| .
This  ||| S:1337 E:1342 ||| DT
burden  ||| S:1342 E:1349 ||| NN
is  ||| S:1349 E:1352 ||| VBZ
even  ||| S:1352 E:1357 ||| RB
greater  ||| S:1357 E:1365 ||| JJR
in  ||| S:1365 E:1368 ||| IN
patients  ||| S:1368 E:1377 ||| NNS
with  ||| S:1377 E:1382 ||| IN
difficult-to-treat  ||| S:1382 E:1401 ||| JJ
disease ||| S:1401 E:1408 ||| NN
.  ||| S:1408 E:1410 ||| .
